SREBP Inhibitor Program (Metabolic)
Fatty liver disease, cardiovascular disease, diabetes
Pre-clinicalActive
Key Facts
Indication
Fatty liver disease, cardiovascular disease, diabetes
Phase
Pre-clinical
Status
Active
Company
About FGH BioTech
FGH BioTech is a preclinical-stage biotech leveraging over 60 years of foundational research in fat metabolism to develop first-in-class small molecule inhibitors of SREBP transcription factors. Its platform targets the root metabolic drivers of prevalent conditions like fatty liver disease, diabetes, cardiovascular disease, and aggressive cancers such as castration-resistant prostate cancer. The company is privately held, pre-revenue, and advancing its lead programs through preclinical proof-of-concept, aiming to address multi-billion-dollar markets with high unmet need.
View full company profile